|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the OPTR 10-K filed Mar 12, 2009. WHEREAS, the Company and the
Executive previously entered into an employment agreement dated March 1,
2001 (the “Prior Agreement”).
WHEREAS,
Optimer is a biopharmaceutical company engaged in the discovery and development
of pharmaceutical products using its proprietary carbohydrate synthesis
technology;
WHEREAS, THE Company wishes for
Executive to continue in his role as Chief Executive Officer and President of
the Company.
WHEREAS,
Cempra is a biopharmaceutical company engaged in the discovery and development
of novel pharmaceutical products;
WHEREAS,
Cempra and Optimer desire to enter into a relationship to identify, develop and
commercialize pharmaceutical products comprising novel Macrolide Antibiotics to
treat infectious diseases.
WHEREAS,
Cempra and Optimer entered into a letter agreement dated November 10, 2005
wherein Optimer and Cempra agreed to execute a detailed agreement regarding the
synthesis by Optimer of Macrolide Antibiotics for Cempra; and
WHEREAS,
Optimer is willing to synthesize Macrolide Antibiotics using its proprietary
carbohydrate synthesis technology, assist Cempra in the development thereof, and
is prepared to grant Cempra a license under such technology to allow Cempra to
develop and commercialize pharmaceutical products arising from this
relationship;
WHEREAS, Optimer is a biopharmaceutical company engaged in the discovery and development of pharmaceutical products using its proprietary carbohydrate synthesis technology;
WHEREAS, Cempra is a biopharmaceutical company engaged in the discovery and development of novel pharmaceutical products;
WHEREAS, Cempra and Optimer desire to enter into a relationship to identify, develop and commercialize pharmaceutical products comprising novel Macrolide Antibiotics to treat infectious diseases.
WHEREAS, Cempra and Optimer entered into a letter agreement dated November 10, 2005 wherein Optimer and Cempra agreed to execute a detailed agreement regarding the synthesis by Optimer of Macrolide Antibiotics for Cempra; and
WHEREAS, Optimer is willing to synthesize Macrolide Antibiotics using its proprietary carbohydrate synthesis technology, assist Cempra in the development thereof, and is prepared to grant Cempra a license under such technology to allow Cempra to develop and commercialize pharmaceutical products arising from this relationship;
WHEREAS, the Company and the Executive previously entered into an employment agreement dated March 1, 2001 (the “Prior Agreement”).
WHEREAS, THE Company wishes for Executive to continue in his role as Chief Executive Officer and President of the Company.
| EXCERPTS ON THIS PAGE:
|
| |||||||
